SRPT
Sarepta Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.50
−2.13%Margins
Gross margin
58.6%
EBITDA margin
-0.7%
EBIT margin
-7.3%
Net margin
-6.9%
FCF margin
-6.7%
-8.9%
Return on equity
-4.3%
Return on assets
-5.6%
Return on invested capital
0.62x
Asset turnover
-$91.7M
Cash from operations
$7.46
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026